The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas

Journal of Neuropathology and Experimental Neurology

Volumn 71, Issue 1, 2012, Pages 73-82

  Horbinski, Craig ^a   Nikiforova, Marina N ^b   Hobbs, Jonathan ^a   Bortoluzzi, Stephanie ^c   Cieply, Kathleen ^b   Dacic, Sanja ^b   Hamilton, Ronald L ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

10q; 1p 19q; Epidermal growth factor receptor; Fluorescence in situ hybridization; Loss of heterozygosity; Microsatellite; Oligodendroglioma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CHROMOSOME 10Q; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 19; COHORT STUDIES; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES;

EID: 84655167685     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e318240fa65     Document Type: Article

References (47)

1. Reifenberger J, Reifenberger G, Liu L, et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-90 (Pubitemid 24345665)
2. Kraus JA, Koopmann J, Kaskel P, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol 1995;54:91-95
3. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-79 (Pubitemid 28482012)
4. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636-45 (Pubitemid 30078545)
5. Perry A, Fuller CE, Banerjee R, et al. Ancillary FISH analysis for 1p and 19q status: Preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci 2003;8:1-9
6. van den Bent MJ, Looijenga LH, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003;97:1276-84 (Pubitemid 36237315)
7. Fallon KB. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004;63: 314-22 (Pubitemid 38429028)
8. Felsberg J, Erkwoh A, Sabel MC, et al. Oligodendroglial tumors: Refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 2004;14:121-30 (Pubitemid 38656383)
9. Kouwenhoven MC, Gorlia T, Kros JM, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol 2009;11:737-46
10. Jenkins RB. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006;66:9852-61 (Pubitemid 44672036)
11. Griffin CA. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006;65:988-94 (Pubitemid 44521799)
12. Labussiere M, Idbaih A, Wang XW, et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology 2010;74:1886-90
13. van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: A report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010;16: 1597-604
14. Ducray F, Idbaih A, de Reynies A, et al. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 2008;7:41
15. Idbaih A, Marie Y, Lucchesi C, et al. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 2008;122:1778-86 (Pubitemid 351413424)
16. Giannini C, Burger PC, Berkey BA, et al. Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 2008;18:360-69 (Pubitemid 351782844)
17. McDonald JM, See SJ, Tremont IW, et al. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 2005;104:1468-77 (Pubitemid 41356162)
18. Eoli M, Bissola L, Bruzzone MG, et al. Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 2006;119: 84-90
19. Fuller CE, Schmidt RE, Roth KA, et al. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol 2003;62:1118-28 (Pubitemid 37413823)
20. Raghavan R, Balani J, Perry A, et al. Pediatric oligodendrogliomas: A study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol 2003;62:530-37 (Pubitemid 36560194)
21. Kreiger PA, Okada Y, Simon S, et al. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol 2005;109: 387-92 (Pubitemid 40637311)
22. Barbashina V, Salazar P, Holland EC, et al. Allelic losses at 1p36 and 19q13 in gliomas: Correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005; 11:1119-28 (Pubitemid 40175761)
23. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999;18:4144-52 (Pubitemid 29363922)
24. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005;64:479-89
25. Miller CR, Dunham CP, Scheithauer BW, et al. Significance of necrosis in grading of oligodendroglial neoplasms: A clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 2006;24:5419-26 (Pubitemid 46623175)
26. Abounader R. Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Rev Anticancer Ther 2009;9:235-45
27. Sasaki H, Zlatescu MC, Betensky RA, et al. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol 2001;159:359-67 (Pubitemid 33704221)
28. Ramirez C, Bowman C, Maurage CA, et al. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumorsVTowards individualized tumor treatment? Neuro Oncol 2010; 12:490-99
29. Jha P, Sarkar C, Pathak P, et al. Detection of allelic status of 1p and 19q by microsatellite-based PCR versus FISH: Limitations and advantages in application to patient management. Diagn Mol Pathol 2011;20:40-47
30. Broholm H, Born PW, Guterbaum D, et al. Detecting chromosomal alterations at 1p and 19q by FISH and DNA fragment analysisVA comparative study in human gliomas. Clin Neuropathol 2008;27:378-87
31. Horbinski C. Practical molecular diagnostics in neuropathology: Making a tough job a little easier. Semin Diagn Pathol 2010;27:105-13
32. Horbinski C, Hamilton RL, Nikiforov Y, et al. Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol 2010;119:641-49
33. Horbinski C, Hobbs J, Cieply K, et al. EGFR expression stratifies oligodendroglioma behavior. Am J Pathol 2011;179:1638-44
34. Snuderl M, Eichler AF, Ligon Kl, et al. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res 2009;15:6430-37
35. Horbinski C, Miller CR, Perry A. Gone FISHing: Clinical lessons learned in brain tumor molecular diagnostics over the last decade. Brain Pathol 2010;21:57-73
36. Woehrer A, Sander P, Haberler C, et al. FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: Procedures and protocols for neuropathological practiceVA publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies. Clin Neuropathol 2011;30:47-55
37. Hashimoto N. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. Cancer 2003;97:2254-61 (Pubitemid 36444069)
38. Okamoto Y. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 2004;108:49-56 (Pubitemid 38961073)
39. Ueki K, Nishikawa R, Nakazato Y, et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002;8:196-201 (Pubitemid 34101478)
40. Perry A, Aldape KD, George DH, et al. Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 2004;101:2318-26 (Pubitemid 39458690)
41. Kitange G, Misra A, Law M, et al. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer 2005;42: 68-77 (Pubitemid 39582821)
42. Lavon I. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res 2007;13:1429-37 (Pubitemid 46450432)
43. Zhou Y-H, Hess KR, Raj VR, et al. Establishment of prognostic models for astrocytic and oligodendroglial brain tumors with standardized quantification of marker gene expression and clinical variables. Biomarker Insights 2010;5:153-68
44. Cowell JK, Barnett GH, Nowak NJ. Characterization of the 1p/19q chromosomal loss in oligodendrogliomas using comparative genomic hybridization arrays (CGHa). J Neuropathol Exp Neurol 2004;63: 151-58 (Pubitemid 38174780)
45. Alvarez K, Kash SF, Lyons-Weiler MA, et al. Reproducibility and performance of virtual karyotyping with SNP microarrays for the detection of chromosomal imbalances in formalin-fixed paraffin-embedded tissues. Diagn Mol Pathol 2010;19:127-34
46. Buckley PG, Alcock L, Heffernan J, et al. Loss of chromosome 1p/19q in oligodendroglial tumors: Refinement of chromosomal critical regions and evaluation of internexin immunostaining as a surrogate marker. J Neuropathol Exp Neurol 2011;70:177-82
47. Franco-Hernandez C, Martinez-Glez V, de Campos JM, et al. Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: Multiplex ligation-dependent probe amplification versus loss of heterozygosity. Cancer Genet Cytogenet 2009;190:93-96